Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

Thomas K. Karikari; Tharick A. Pascoal; Nicholas J. Ashton; Shorena Janelidze; Andréa Lessa Benedet; Juan Lantero‐Rodriguez; Mira Chamoun; Mélissa Savard; Min Su Kang; Joseph Therriault; Michael Schöll; Gassan Massarweh; Jean-Paul Soucy; Kina Höglund; Gunnar Brinkmalm; Niklas Mattsson; Sebastian Palmqvist; Serge Gauthier; Erik Stomrud; Henrik Zetterberg; Oskar Hansson; Pedro Rosa‐Neto; Kaj Blennow

doi:10.1016/s1474-4422(20)30071-5

Keywords

MedicineBiomarkerCohortDementiaProspective cohort studyInternal medicineOncologyDiseaseCohort studyCognitive declineFrontotemporal dementiaAlzheimer's disease

Affiliated Institutions

Related Publications

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Leslie M. Shaw , Hugo Vanderstichele , Małgorzata Knapik-Czajka +12 more

Abstract Objective Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods Am...

2009 Annals of Neurology 2041 citations

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease

Nicolai Franzmeier , Emrah Düzel , Frank Jessen +53 more

Patients with Alzheimer's disease vary in their ability to sustain cognitive abilities in the presence of brain pathology. A major open question is which brain mechanisms may su...

2018 Brain 117 citations

Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia

William J. Jagust

Abstract Background The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by the development of the brain imaging techniques of ma...

2006 Alzheimer s & Dementia 72 citations

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Clifford R. Jack , David A. Bennett , Kaj Blennow +11 more

Biomarkers have become an essential component of Alzheimer disease (AD) research and because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used in...

2016 Neurology 1739 citations

Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [ <sup>11</sup> C]PiB

Susan M. Resnick , Jitka Sojkova , Zhou Yu +9 more

Higher Abeta deposition is associated with greater longitudinal decline in mental status and verbal memory in the preceding years. The differential association for verbal but no...

2010 Neurology 287 citations

Publication Info

Year: 2020
Type: article
Volume: 19
Issue: 5
Pages: 422-433
Citations: 1244
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1244

OpenAlex

Cite This

APA Style

                            
                                
                                    Thomas K. Karikari, 
                                
                                    Tharick A. Pascoal, 
                                
                                    Nicholas J. Ashton
                                
                                et al.
                            
                            (2020). 
                            Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. 
                            The Lancet Neurology
                            , 19
                            (5)
                            , 422-433.
                            https://doi.org/10.1016/s1474-4422(20)30071-5
                        

Identifiers

DOI: 10.1016/s1474-4422(20)30071-5